Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis.
The objectives were to determine the prevalence and clinical significance of anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with juvenile idiopathic arthritis (JIA). Anti-CCP antibodies were checked by ELISA in 68 children with JIA, 38 males and 30 females with mean age of 10.6 (+/-4.02) years and disease duration of 3.7 (+/-1.8) years. Thirty-eight (56%) patients had polyarticular disease, 20 (29%) patients had oligoarticular disease and 10 (15%) patients had systemic onset disease. All patients had their antinuclear antibodies (ANA), rheumatoid factor (RF) and ESR checked and x-rays performed to look for erosions. Results were compared to those of 20 healthy children, 14 children with juvenile systemic lupus erythematosus (JSLE) and 30 adults with rheumatoid arthritis (RA). Anti-CCP antibodies were positive in 14/68 (20.6%) patients with JIA, all had polyarticular-onset disease. All patients with positive anti-CCP antibodies had RF-positive polyarthritis. Anti-CCP antibodies were negative in all patients with oligoarticular-onset and systemic-onset disease including 2 patients with extended oligoarthritis. Anti-CCP antibodies were negative in healthy and JSLE controls but were positive in 20/30 (66.5%) adults with RA. Anti-CCP antibodies correlated significantly with joint erosions in patients with JIA (p = 0.004) but no significant relation was found between anti-CCP antibodies and ANA positivity or raised ESR. These data confirm that anti-CCP antibodies are less prevalent in JIA than adult RA but are detectable in a significant proportion of RF-positive patients with polyarticular-onset JIA. The current study showed significant relation between anti-CCP positivity and erosive joint disease in JIA.
Habib
H M
HM
Department of Rheumatology & Rehabilitation, Mansoura University, Mansoura, Egypt. heshamhabib509@hotmail.com
Mosaad
Y M
YM
Youssef
H M
HM
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood* / Q000276:immunology*; D034961:Antigens, Nuclear / Q000276:immunology* / Q000378:metabolism; D001171:Arthritis, Juvenile / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004534:Egypt; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology; D008297:Male; D010456:Peptides, Cyclic / Q000276:immunology*; D015995:Prevalence; D012217:Rheumatoid Factor / Q000276:immunology* / Q000378:metabolism
D000906:Antibodies; D034961:Antigens, Nuclear; D010456:Peptides, Cyclic; D012217:Rheumatoid Factor